165 related articles for article (PubMed ID: 27458005)
1. Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.
Wang JQ; Beutler B; Goodnow CC; Horikawa K
Blood; 2016 Sep; 128(12):1604-8. PubMed ID: 27458005
[TBL] [Abstract][Full Text] [Related]
2. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.
Wang JQ; Jeelall YS; Beutler B; Horikawa K; Goodnow CC
J Exp Med; 2014 Mar; 211(3):413-26. PubMed ID: 24534189
[TBL] [Abstract][Full Text] [Related]
3. Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses.
Nündel K; Green NM; Shaffer AL; Moody KL; Busto P; Eilat D; Miyake K; Oropallo MA; Cancro MP; Marshak-Rothstein A
J Immunol; 2015 Mar; 194(6):2504-12. PubMed ID: 25681333
[TBL] [Abstract][Full Text] [Related]
4. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
5. Genetic dissection of TLR9 reveals complex regulatory and cryptic proinflammatory roles in mouse lupus.
Leibler C; John S; Elsner RA; Thomas KB; Smita S; Joachim S; Levack RC; Callahan DJ; Gordon RA; Bastacky S; Fukui R; Miyake K; Gingras S; Nickerson KM; Shlomchik MJ
Nat Immunol; 2022 Oct; 23(10):1457-1469. PubMed ID: 36151396
[TBL] [Abstract][Full Text] [Related]
6. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
7. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells.
Ouk C; Roland L; Gachard N; Poulain S; Oblet C; Rizzo D; Saintamand A; Lemasson Q; Carrion C; Thomas M; Balabanian K; Espéli M; Parrens M; Soubeyran I; Boulin M; Faumont N; Feuillard J; Vincent-Fabert C
Front Immunol; 2021; 12():641692. PubMed ID: 34017329
[TBL] [Abstract][Full Text] [Related]
8. Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis.
Pagni PP; Traub S; Demaria O; Chasson L; Alexopoulou L
Autoimmunity; 2010 Jun; 43(4):275-87. PubMed ID: 20187710
[TBL] [Abstract][Full Text] [Related]
9. A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation.
An B; Zhu S; Li T; Wu J; Zang G; Lv X; Qiao Y; Huang J; Shao Y; Cui J; Liu YJ; Chen J
Front Cell Dev Biol; 2020; 8():262. PubMed ID: 32391356
[TBL] [Abstract][Full Text] [Related]
10. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.
Kim YM; Brinkmann MM; Paquet ME; Ploegh HL
Nature; 2008 Mar; 452(7184):234-8. PubMed ID: 18305481
[TBL] [Abstract][Full Text] [Related]
11.
Yu X; Li W; Deng Q; Li L; Hsi ED; Young KH; Zhang M; Li Y
Cancer Res; 2018 May; 78(10):2457-2462. PubMed ID: 29703722
[TBL] [Abstract][Full Text] [Related]
12. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
Schmidt K; Sack U; Graf R; Winkler W; Popp O; Mertins P; Sommermann T; Kocks C; Rajewsky K
Front Immunol; 2020; 11():602868. PubMed ID: 33343574
[TBL] [Abstract][Full Text] [Related]
13. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cooperation and crosstalk between
Wang JQ; Jeelall YS; Humburg P; Batchelor EL; Kaya SM; Yoo HM; Goodnow CC; Horikawa K
J Exp Med; 2017 Sep; 214(9):2759-2776. PubMed ID: 28701369
[No Abstract] [Full Text] [Related]
15. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors.
Yamaguchi T; Kawabata K; Koizumi N; Sakurai F; Nakashima K; Sakurai H; Sasaki T; Okada N; Yamanishi K; Mizuguchi H
Hum Gene Ther; 2007 Aug; 18(8):753-62. PubMed ID: 17685831
[TBL] [Abstract][Full Text] [Related]
16. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
Front Immunol; 2019; 10():95. PubMed ID: 30761150
[TBL] [Abstract][Full Text] [Related]
17. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking.
Fukui R; Saitoh S; Kanno A; Onji M; Shibata T; Ito A; Onji M; Matsumoto M; Akira S; Yoshida N; Miyake K
Immunity; 2011 Jul; 35(1):69-81. PubMed ID: 21683627
[TBL] [Abstract][Full Text] [Related]
18. N-glycosylation of UNC93B1 at a Specific Asparagine Residue Is Required for TLR9 Signaling.
Song HS; Park S; Huh JW; Lee YR; Jung DJ; Yang C; Kim SH; Kim HM; Kim YM
Front Immunol; 2022; 13():875083. PubMed ID: 35874766
[TBL] [Abstract][Full Text] [Related]
19. TLR9 Signaling Suppresses the Canonical Plasma Cell Differentiation Program in Follicular B Cells.
Baptista BJA; Granato A; Canto FB; Montalvão F; Tostes L; de Matos Guedes HL; Coutinho A; Bellio M; Vale AM; Nobrega A
Front Immunol; 2018; 9():2281. PubMed ID: 30546358
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.
Minderman M; Lantermans H; van der Zwaan C; Hoogendijk AJ; van den Biggelaar M; Kersten MJ; Spaargaren M; Pals ST
Blood Cancer J; 2023 Aug; 13(1):125. PubMed ID: 37591861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
